

**Respiratory Diagnostics Market by Product & Services (Devices, Reagents, Software), Test (PFT, Peak Flow, Spirometry), OSA, Imaging (X-ray, CT, MRI, PET), Molecular (PCR, DNA Sequencing), Indication (Lung Cancer, Asthma, COPD, TB) - Global Forecast to 2029**

Market Report | 2023-11-28 | 338 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global respiratory diagnostics market is projected to reach USD 8.2 billion by 2029 from USD 5.6 billion in 2023, at a CAGR of 6.6% during the forecast period. The growth of the respiratory diagnostics market is propelled by a combination of factors that collectively address the increasing global burden of respiratory diseases. Technological advancements, particularly in diagnostic tools and imaging techniques, have greatly improved the precision and efficiency of respiratory diagnostics, allowing for early detection and more effective management of conditions like COPD, TB, and lung cancer etc. Rising awareness among healthcare professionals and the public about the importance of early diagnosis, coupled with government-led screening programs, has contributed to a higher demand for respiratory diagnostic tests. The emergence of the COVID-19 pandemic has added a new dimension to the market, emphasizing the urgency of rapid and accurate diagnostics for respiratory infections. Changes in regulations, such as new requirements for product approval, labeling, or quality standards, can restrain the market growth.

"Instruments and Devices segment accounted for the largest share and is expected to grow at the highest rate during the forecast period."

Due to the continuous advancements in diagnostic technologies, including imaging devices, spirometers, and other respiratory diagnostic instruments. Additionally, the increasing prevalence of respiratory diseases worldwide has driven the demand for sophisticated and accurate diagnostic tools, amplifying the significance of this segment. Innovations in point-of-care testing devices and portable diagnostic instruments have further fueled the growth of the Instruments and Devices segment, enabling healthcare professionals to conduct rapid and precise respiratory assessments. Hence, the aforementioned factors are driving the

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

growth of the respiratory diagnostics market.

"The Mechanical tests segment accounted for the largest share and is expected to grow at the highest rate during the forecast period."

Mechanical tests encompass a range of diagnostic tools, such as spirometers and peak flow meters, which play a significant role in evaluating lung capacity and airflow. The growing prevalence of respiratory disorders, coupled with the need for accurate diagnosis and monitoring, has propelled the demand for mechanical tests. Additionally, advancements in technology have enhanced the efficiency and accuracy of these tests, further driving their widespread adoption. Increasing demand for precise and comprehensive mechanical assessments of respiratory function will drive the growth of the respiratory diagnostics market.

"Asthma segment accounted for the largest share of the global respiratory diagnostics market."

The rise in environmental pollutants, changing lifestyles, and genetic factors contribute to the growing incidence of asthma, necessitating advanced diagnostic solutions. The Asthma segment encompasses a range of diagnostic modalities, including pulmonary function tests, imaging techniques, and biomarker assessments, providing a comprehensive approach to asthma diagnosis and management. The continuous research and development efforts in this segment, with a focus on personalized medicine, are driving the growth of the respiratory diagnostics market.

"Hospitals and clinics end-user segment held the largest market share growing at the highest CAGR during the forecast period of the global respiratory diagnostics market."

The rise in respiratory diseases, coupled with the growing awareness of the importance of early detection, has led to a surge in diagnostic procedures conducted in these facilities. The Hospitals and Clinics segment encompasses a wide range of diagnostic tools and services, including imaging studies, pulmonary function tests, and molecular diagnostics, providing a comprehensive approach to respiratory health assessment. By the increasing demand for respiratory diagnostic services in healthcare settings, where hospitals and clinics play a central role in disease diagnosis, management, and treatment, position this segment at the forefront of addressing the evolving challenges in respiratory diagnostics.

"North America to Witness Significant Growth From 2023 to 2029."

Respiratory diagnostics market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2022, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) during the forecast period. However, the North American market held the largest market share of the global market. North America stands as the frontrunner in the respiratory diagnostics market, commanding the largest market share throughout the forecast period. This leadership position is attributed to several factors, including a well-established healthcare infrastructure, high prevalence of respiratory diseases, and robust research and development activities in the region. The sophisticated diagnostic technologies available, coupled with a strong emphasis on early disease detection and management, contribute to the region's dominance. Additionally, increased healthcare spending, a rising geriatric population, and growing awareness about respiratory health further propel market growth.

Breakdown of supply-side primary interviews: - By Company Type: Tier 1 - 35%, Tier 2 - 40%, and Tier 3 - 25% - By Designation: C-level - 30%, Director-level - 23%, and Others - 47% - By Region: North America - 35%, Europe - 20%, APAC - 25%, Latin America - 13%, Middle East & Africa - 7%

Some of the prominent players in the respiratory diagnostics market are Koninklijke Philips N.V. (Netherlands), BD (US), Abbott (US), Thermo Fisher Scientific Inc. (US), GE HealthCare (US), Bio-Rad Laboratories, Inc. (US), BioMerieux (France), Revvity, Inc. (US), Seegene Inc. (South Korea), Nihon Kohden Corporation (Japan), Vitalograph (UK), SDI Diagnostics (US), ResMed Inc. (US), Siemens Healthcare GmbH (Germany), Cosmed (Italy), Hologic, Inc. (US), Qiagen (Netherlands), Vyair (US), Visby Medical, Inc (US), Briota Technologies Private Limited (India), Bird Healthcare (Australia), Lowenstein Medical Technology (Germany), ProAxis (Northern Ireland), ndd Medical Technologies (US) and Compumedics Limited (Australia).

Research Coverage

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

This report studies respiratory diagnostics market based on products and services, test type, disease indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

#### Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

- Analysis of key drivers (rising prevalence of respiratory diseases, Increasing incidence rate of preterm births, growing outbreaks of infectious diseases affecting the respiratory system, growing population with sleep disorders, rising R&D investments for technological advancement of medical devices), restraints (unfavorable reimbursement scenario for respiratory care diagnostics), opportunities (high respiratory diagnostics market growth opportunities in Asia Pacific and Latin America, improving POC diagnostics, growing awareness about the ill effects of untreated sleep apnea), and challenges (low awareness and lack of diagnosis of respiratory diseases) influencing the growth of respiratory diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in respiratory diagnostics market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of respiratory diagnostics across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in respiratory diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in respiratory diagnostics market.

#### Table of Contents:

1□INTRODUCTION□	42
1.1□STUDY OBJECTIVES□	42
1.2□MARKET DEFINITION□	43
1.3□INCLUSIONS & EXCLUSIONS□	43
1.4□MARKET SCOPE□	44
1.4.1□MARKETS COVERED□	44
1.4.2□REGIONS COVERED□	45
1.4.3□YEARS CONSIDERED□	45
1.4.4□CURRENCY CONSIDERED□	46
1.5□STAKEHOLDERS□	46
1.6□SUMMARY OF CHANGES□	46
1.6.1□RECESSION IMPACT□	47
2□RESEARCH METHODOLOGY□	48
2.1□RESEARCH DATA□	48
FIGURE 1□RESEARCH DESIGN□	48
2.1.1□SECONDARY DATA□	49
2.1.1.1□Key data from secondary sources□	50
2.1.2□PRIMARY DATA□	50
FIGURE 2□PRIMARY SOURCES□	50
2.1.2.1□Key industry insights□	51

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.1.2.2	Key data from primary sources	52
2.1.2.3	Breakdown of primary interviews	52
FIGURE 3	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	52
FIGURE 4	BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION	53
FIGURE 5	BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	53
2.2	MARKET SIZE ESTIMATION	54
FIGURE 6	SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS	54
FIGURE 7	REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V.	55
FIGURE 8	SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2022)	55
FIGURE 9	CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	57
FIGURE 10	CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS	58
FIGURE 11	TOP-DOWN APPROACH	59
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	60
FIGURE 12	MARKET DATA TRIANGULATION METHODOLOGY	60
2.4	MARKET SHARE ESTIMATION	61
2.5	STUDY ASSUMPTIONS	61
2.6	RESEARCH LIMITATIONS	62
2.6.1	METHODOLOGY-RELATED LIMITATIONS	62
2.6.2	SCOPE-RELATED LIMITATIONS	62
2.7	RISK ASSESSMENT	62
TABLE 1	RISK ASSESSMENT: RESPIRATORY DIAGNOSTICS MARKET	62
2.8	IMPACT OF RECESSION ON RESPIRATORY DIAGNOSTICS MARKET	62
3	EXECUTIVE SUMMARY	63
FIGURE 13	RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2023 VS. 2029 (USD MILLION)	63
FIGURE 14	RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2029 (USD MILLION)	64
FIGURE 15	RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2023 VS. 2029 (USD MILLION)	64
FIGURE 16	RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION)	65
FIGURE 17	GEOGRAPHICAL SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET	66
4	PREMIUM INSIGHTS	67
4.1	RESPIRATORY DIAGNOSTICS MARKET OVERVIEW	67
FIGURE 18	TECHNOLOGICAL ADVANCEMENTS AND GROWTH IN GERIATRIC POPULATION TO DRIVE MARKET	67
4.2	GEOGRAPHICAL GROWTH OPPORTUNITIES: RESPIRATORY DIAGNOSTICS MARKET	68
FIGURE 19	NORTH AMERICA COMMANDED LARGEST MARKET SHARE IN 2022	68
4.3	REGIONAL MIX: RESPIRATORY DIAGNOSTICS MARKET	68
FIGURE 20	ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD	68
4.4	DEVELOPED VS. EMERGING ECONOMIES: RESPIRATORY DIAGNOSTICS MARKET, 2023 VS. 2029 (USD MILLION)	69
FIGURE 21	EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING STUDY PERIOD	69
5	MARKET OVERVIEW	70
5.1	INTRODUCTION	70
5.2	MARKET DYNAMICS	70
FIGURE 22	DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES: RESPIRATORY DIAGNOSTICS MARKET	70
5.2.1	DRIVERS	71
5.2.1.1	Rising prevalence of respiratory diseases	71
5.2.1.1.1	Growth in global geriatric population	72
FIGURE 23	GLOBAL GERIATRIC POPULATION, BY REGION	72
5.2.1.1.2	Urbanization and growing pollution levels	72
FIGURE 24	PERCENTAGE OF DEATHS CAUSED BY HOUSEHOLD AND AMBIENT AIR POLLUTION, BY DISEASE (APPROXIMATELY, EVERY	

YEAR) 73

5.2.1.1.3 Rising prevalence of tobacco smoking 73

TABLE 2 PREVALENCE OF LIFESTYLE DISEASES AND RELATED DEATHS 73

5.2.1.1.4 Changing lifestyle, obesity, and physical inactivity 74

5.2.1.2 Increasing rate of preterm births 74

TABLE 3 TOP 10 COUNTRIES WITH HIGHEST NUMBER OF PRETERM BIRTHS, 2020 74

FIGURE 25 PRETERM BIRTH BY GESTATIONAL AGE AND REGION, 2020 75

5.2.1.3 Increasing outbreaks of infectious diseases affecting respiratory system 75

5.2.1.4 Growing population with sleep disorders 75

5.2.1.5 Rising R&D investments for technologically advanced medical devices 76

5.2.2 RESTRAINTS 76

5.2.2.1 Unfavorable reimbursement policies 76

5.2.2.2 Availability of low-cost products from local manufacturers 77

5.2.3 OPPORTUNITIES 77

5.2.3.1 Increased market growth in Asia Pacific and Latin America 77

5.2.3.2 Improving POC diagnostics 77

5.2.3.3 Increasing ill effects of untreated sleep apnea 78

TABLE 4 INITIATIVES TO PROMOTE AWARENESS ABOUT ILL EFFECTS OF UNTREATED SLEEP APNEA 78

5.2.4 CHALLENGES 79

5.2.4.1 Low awareness and lack of diagnosis of respiratory diseases 79

5.3 INDUSTRY TRENDS 80

5.3.1 RISING DEMAND FOR POINT-OF-CARE DIAGNOSTIC DEVICES 80

5.3.2 FOCUS OF MARKET PLAYERS ON GEOGRAPHICAL EXPANSIONS 80

5.3.3 INCREASING NUMBER OF REAGENT RENTAL AGREEMENTS 80

5.4 SUPPLY CHAIN ANALYSIS 81

FIGURE 26 SUPPLY CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET 82

5.5 TARIFF AND REGULATORY ANALYSIS 82

5.5.1 REGULATORY ANALYSIS 82

5.5.1.1 North America 82

5.5.1.1.1 US 82

TABLE 5 US: CLASSIFICATION OF MEDICAL EQUIPMENT 82

TABLE 6 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 83

5.5.1.1.2 Canada 83

TABLE 7 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 83

5.5.1.2 Europe 84

TABLE 8 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 84

5.5.1.3 Asia Pacific 84

5.5.1.3.1 Japan 84

TABLE 9 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85

5.5.1.3.2 China 85

TABLE 10 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85

5.5.1.3.3 India 86

5.5.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86

5.5.2.1 North America 86

TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86

5.5.2.2 Europe 87

TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

### 5.5.2.3 Rest of the World 88

TABLE 13 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88

### 5.6 ECOSYSTEM MARKET MAP 89

FIGURE 27 ECOSYSTEM MARKET MAP: RESPIRATORY DIAGNOSTICS MARKET 89

### 5.7 VALUE CHAIN ANALYSIS 90

FIGURE 28 VALUE CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET 91

### 5.8 TECHNOLOGY ANALYSIS 91

#### 5.8.1 KEY TECHNOLOGIES 91

5.8.1.1 Digitalization of diagnostic tests 91

#### 5.8.2 ADJACENT TECHNOLOGIES 92

5.8.2.1 Rapid respiratory diagnostic kits 92

#### 5.8.3 COMPLEMENTARY TECHNOLOGIES 93

### 5.9 PATENT ANALYSIS 94

#### 5.9.1 PATENT PUBLICATION TRENDS 94

FIGURE 29 PATENT PUBLICATION TRENDS, 2013-2023 94

#### 5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS 94

FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013-NOVEMBER 2023) 95

FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013-NOVEMBER 2023) 95

### 5.10 TRADE ANALYSIS 96

TABLE 14 TOP EXPORTERS OF RESPIRATORY DIAGNOSTICS DEVICES, 2022 (USD MILLION) 96

### 5.11 CASE STUDY ANALYSIS 97

TABLE 15 MONITORING OF COPD PATIENTS AT HOME 97

TABLE 16 REPLACEMENT PATTERN OF VENTILATORS IN DEVELOPED ECONOMIES VS. EMERGING ECONOMIES 97

TABLE 17 VOLUME DATA OF VENTILATORS, ICU VENTILATORS, PORTABLE VENTILATORS, PAP DEVICES, CPAP DEVICES, BIPAP DEVICES, AND SPIROMETERS 98

### 5.12 PORTER'S FIVE FORCES ANALYSIS 98

TABLE 18 PORTER'S FIVE FORCES ANALYSIS 98

5.12.1 THREAT OF NEW ENTRANTS 99

5.12.2 THREAT OF SUBSTITUTES 99

5.12.3 BARGAINING POWER OF SUPPLIERS 100

5.12.4 BARGAINING POWER OF BUYERS 100

5.12.5 INTENSITY OF COMPETITIVE RIVALRY 100

### 5.13 KEY CONFERENCES & EVENTS 100

TABLE 19 LIST OF KEY CONFERENCES & EVENTS IN 2023-2024 100

### 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 101

5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 101

FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES 101

TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 102

5.14.2 BUYING CRITERIA 102

FIGURE 33 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES 102

TABLE 21 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES 102

### 5.15 PRICING ANALYSIS 103

TABLE 22 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC DEVICES, BY PRODUCT TYPE (USD) 103

5.15.1 AVERAGE SELLING PRICE TREND, BY REGION 103

### 5.16 ADJACENT MARKETS 103

FIGURE 34 ADJACENT MARKETS OF RESPIRATORY DIAGNOSTICS MARKET 103

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.17	UNMET NEEDS IN RESPIRATORY DIAGNOSTIC DEVICES	104
5.18	USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET	105
TABLE 23 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET		
5.18.1	USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE IN HEALTHCARE	105
5.19	REIMBURSEMENT SCENARIO ANALYSIS	106
TABLE 24 REIMBURSEMENT SCENARIO: RESPIRATORY DIAGNOSTICS MARKET		
6	RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE	108
6.1	INTRODUCTION	109
TABLE 25 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)		
6.2	INSTRUMENTS AND DEVICES	109
6.2.1	INCREASING PREVALENCE OF RESPIRATORY DISEASES TO DRIVE MARKET	109
TABLE 26 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS AND DEVICES, BY COUNTRY, 2021-2029 (USD MILLION)		
6.3	ASSAYS AND REAGENTS	110
6.3.1	RIISING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO DRIVE MARKET	110
TABLE 27 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS AND REAGENTS, BY COUNTRY, 2021-2029 (USD MILLION)		
6.4	SERVICES AND SOFTWARE	111
6.4.1	INTRODUCTION TO ADVANCED AND AUTOMATED TECHNOLOGIES TO DRIVE MARKET	111
TABLE 28 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2021-2029 (USD MILLION)		
7	RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE	113
7.1	INTRODUCTION	114
TABLE 29 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)		
7.2	MECHANICAL TESTS	114
TABLE 30 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION)		
TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)		
7.2.1	PULMONARY FUNCTION TESTS	116
TABLE 32 PULMONARY FUNCTION TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)		
TABLE 33 PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)		
7.2.2	SPIROMETRY	117
7.2.2.1	Spirometry to dominate pulmonary function tests segment during forecast period	117
TABLE 34 SPIROMETRY TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)		
7.2.3	PEAK FLOW TESTS	118
7.2.3.1	Precise measurements from peak flow tests to help focus on effective treatment plans	118
TABLE 35 PEAK FLOW TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)		
7.2.4	OBSTRUCTIVE SLEEP APNEA TESTS	119
7.2.4.1	Increased focus on diagnosis of sleep apnea at early stages to drive segment	119
TABLE 36 OBSTRUCTIVE SLEEP APNEA TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)		
7.2.5	OTHER MECHANICAL TESTS	120
TABLE 37 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)		
7.3	IMAGING TESTS	121
TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2021-2029 (USD MILLION)		
TABLE 39 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)		
7.3.1	X-RAY	123
7.3.1.1	Increased investments in advanced radiographic technologies for superior lung imaging to drive segment	123
TABLE 40 X-RAY MARKET, BY COUNTRY, 2021-2029 (USD MILLION)		
7.3.2	COMPUTED TOMOGRAPHY	123
7.3.2.1	Growing focus on manufacturing high-resolution CT imaging for comprehensive respiratory assessments to drive	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

segment123

TABLE 41COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2021-2029 (USD MILLION)124

?

7.3.3MAGNETIC RESONANCE IMAGING124

7.3.3.1Rising investments in AI-enhanced MRI analysis for precise respiratory assessment to drive segment124

TABLE 42MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2021-2029 (USD MILLION)125

7.3.4POSITRON EMISSION TOMOGRAPHY125

7.3.4.1Increased focus on effective treatment and management of lung cancer to drive segment125

TABLE 43POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2021-2029 (USD MILLION)126

7.3.5OTHER IMAGING TESTS126

TABLE 44OTHER IMAGING TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)127

7.4TRADITIONAL DIAGNOSTIC TESTS127

TABLE 45RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2021-2029 (USD MILLION)128

TABLE 46RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)128

7.4.1IMMUNODIAGNOSTICS129

7.4.1.1Increased focus on rapid disease diagnosis to drive segment129

TABLE 47IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)129

7.4.2BIOCHEMICAL CHARACTERIZATION130

7.4.2.1Rising number of collaborations among biochemical laboratories for developing advanced diagnostics to drive segment130

TABLE 48BIOCHEMICAL CHARACTERIZATION MARKET, BY COUNTRY, 2021-2029 (USD MILLION)130

7.4.3MICROSCOPY131

7.4.3.1Lack of sensitivity toward emerging diseases and potential virus bioterrorism to limit market131

TABLE 49MICROSCOPY MARKET, BY COUNTRY, 2021-2029 (USD MILLION)131

7.5MOLECULAR DIAGNOSTIC TESTS132

TABLE 50RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2021-2029 (USD MILLION)132

TABLE 51RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)133

7.5.1PCR133

7.5.1.1Development of portable, real-time PCR machines and assays to drive segment133

TABLE 52PCR MARKET, BY COUNTRY, 2021-2029 (USD MILLION)134

7.5.2NUCLEIC ACID AMPLIFICATION134

7.5.2.1Growing focus on automated nucleic acid amplification processes to drive segment134

TABLE 53NUCLEIC ACID AMPLIFICATION MARKET, BY COUNTRY, 2021-2029 (USD MILLION)135

7.5.3IN SITU HYBRIDIZATION135

7.5.3.1Increased adoption of automated technologies for streamlined respiratory testing to drive segment135

TABLE 54IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2021-2029 (USD MILLION)136

7.5.4DNA SEQUENCING AND NEXT-GENERATION SEQUENCING136

7.5.4.1Rising number of research activities on sequencing-based biomarkers to drive segment136

TABLE 55DNA SEQUENCING AND NEXT GENERATION SEQUENCING MARKET, BY COUNTRY, 2021-2029 (USD MILLION)137

7.5.5MICROARRAYS137

7.5.5.1Easy and effective detection of genetic signatures across multiple genes to drive segment137

TABLE 56MICROARRAYS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)138

7.5.6OTHER MOLECULAR DIAGNOSTIC TESTS138

TABLE 57OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)139

8RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION140

8.1INTRODUCTION141

TABLE 58RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)141

8.2TUBERCULOSIS141

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



8.2.1	INCREASING EARLY SCREENING PROGRAMS AND FUNDS BY GOVERNMENT TO DRIVE MARKET	141
TABLE 59	RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2021-2029 (USD MILLION)	142
8.3	ASTHMA	142
8.3.1	INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET	142
TABLE 60	RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2021-2029 (USD MILLION)	143
8.4	LUNG CANCER	143
8.4.1	INCREASING NUMBER OF TOBACCO CONSUMERS TO DRIVE MARKET	143
TABLE 61	RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021-2029 (USD MILLION)	144
8.5	CHRONIC OBSTRUCTIVE PULMONARY DISEASE	144
8.5.1	INCREASED INVESTMENT IN RESEARCH GRANTS FOR NOVEL BIOMARKERS AND DIAGNOSTIC TECHNOLOGIES TO DRIVE MARKET	144
TABLE 62	RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2021-2029 (USD MILLION)	145
8.6	OTHER RESPIRATORY DISEASES	145
TABLE 63	RESPIRATORY DIAGNOSTICS MARKET FOR OTHER RESPIRATORY DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)	146
9	RESPIRATORY DIAGNOSTICS MARKET, BY END USER	147
9.1	INTRODUCTION	148
TABLE 64	RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	148
9.2	HOSPITALS AND CLINICS	148
9.2.1	HOSPITALS AND CLINICS SEGMENT TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD	148
TABLE 65	RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2029 (USD MILLION)	149
9.3	DIAGNOSTIC LABORATORIES	149
9.3.1	EASY AND AFFORDABLE TESTING PROCESSES WITH TIMELY AND ACCURATE RESULTS TO DRIVE MARKET	149
TABLE 66	RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)	150
9.4	OTHER END USERS	150
TABLE 67	RESPIRATORY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION)	151
10	RESPIRATORY DIAGNOSTICS MARKET, BY REGION	152
10.1	INTRODUCTION	153
FIGURE 35	RESPIRATORY DIAGNOSTICS MARKET REGIONAL SNAPSHOT	153
TABLE 68	RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2021-2029 (USD MILLION)	154
10.2	NORTH AMERICA	155
FIGURE 36	NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT	155
TABLE 69	NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	156
TABLE 70	NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	156
TABLE 71	NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	156
TABLE 72	NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	157
TABLE 73	NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	157
TABLE 74	NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	157
TABLE 75	NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	158
TABLE 76	NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	158
TABLE 77	NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	159
TABLE 78	NORTH AMERICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	159
10.2.1	NORTH AMERICA: RECESSION IMPACT	159
10.2.2	US	160
10.2.2.1	US to dominate North American respiratory diagnostics market during forecast period	160
TABLE 79	US: KEY MACROINDICATORS	160

TABLE 80	US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	161
TABLE 81	US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	161
TABLE 82	US: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	161
TABLE 83	US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	162
TABLE 84	US: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	162
TABLE 85	US: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	162
TABLE 86	US: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	163
TABLE 87	US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	163
TABLE 88	US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	164
10.2.3	CANADA	164
10.2.3.1	Growing geriatric population and increasing awareness about early diagnosis of respiratory diseases to drive market	164
TABLE 89	CANADA: COPD AND ASTHMA STATISTICS (2019 VS. 2020)	164
TABLE 90	CANADA: KEY MACROINDICATORS	165
TABLE 91	CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	165
TABLE 92	CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	166
TABLE 93	CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	166
TABLE 94	CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	166
TABLE 95	CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	167
TABLE 96	CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	167
TABLE 97	CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	168
TABLE 98	CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	168
TABLE 99	CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	169
10.3	EUROPE	169
TABLE 100	EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	169
TABLE 101	EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	170
TABLE 102	EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	170
TABLE 103	EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	170
TABLE 104	EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	171
TABLE 105	EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	171
TABLE 106	EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	171
TABLE 107	EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	172
TABLE 108	EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	172
TABLE 109	EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	173
10.3.1	EUROPE: RECESSION IMPACT	173
10.3.2	GERMANY	173
10.3.2.1	Increasing public healthcare expenditure to drive market	173
TABLE 110	GERMANY: KEY MACROINDICATORS	174
TABLE 111	GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	174
TABLE 112	GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	174
TABLE 113	GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	175
TABLE 114	GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	175
TABLE 115	GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	175
TABLE 116	GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	176
TABLE 117	GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	176

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

TABLE 118	GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	177
TABLE 119	GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	177
10.3.3	FRANCE	177
10.3.3.1	Increasing prevalence of COPD and growing geriatric population to drive market	177
TABLE 120	FRANCE: KEY MACROINDICATORS	178
TABLE 121	FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	178
TABLE 122	FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	178
TABLE 123	FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	179
TABLE 124	FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	179
TABLE 125	FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	179
TABLE 126	FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	180
TABLE 127	FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	180
TABLE 128	FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	181
TABLE 129	FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	181
10.3.4	UK	181
10.3.4.1	Rising number of hospitals and increasing government funding to drive market	181
TABLE 130	UK: KEY MACROINDICATORS	182
TABLE 131	UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	182
TABLE 132	UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	182
TABLE 133	UK: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	183
TABLE 134	UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	183
TABLE 135	UK: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	183
TABLE 136	UK: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	184
TABLE 137	UK: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	184
TABLE 138	UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	185
TABLE 139	UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	185
10.3.5	ITALY	185
10.3.5.1	Unfavorable reforms and reduction in healthcare expenditure by government to limit market	185
TABLE 140	ITALY: KEY MACROINDICATORS	186
TABLE 141	ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	186
TABLE 142	ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	187
TABLE 143	ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	187
TABLE 144	ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	187
TABLE 145	ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	188
TABLE 146	ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	188
TABLE 147	ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	189
TABLE 148	ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	189
TABLE 149	ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	189
10.3.6	SPAIN	190
10.3.6.1	Increasing healthcare spending and growing demand for home care services to drive market	190
TABLE 150	SPAIN: KEY MACROINDICATORS	190
TABLE 151	SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	191
TABLE 152	SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	191
TABLE 153	SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	191

TABLE 154	SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	192
TABLE 155	SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	192
TABLE 156	SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	192
TABLE 157	SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	193
TABLE 158	SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	193
TABLE 159	SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	194
10.3.7	REST OF EUROPE	194
TABLE 160	REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	194
TABLE 161	REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	195
TABLE 162	REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	195
TABLE 163	REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	195
TABLE 164	REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	196
TABLE 165	REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	196
TABLE 166	REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	197
TABLE 167	REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	197
TABLE 168	REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	198
10.4	ASIA PACIFIC	198
FIGURE 37	ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT	199
TABLE 169	ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	200
TABLE 170	ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	200
TABLE 171	ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	200
TABLE 172	ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	201
TABLE 173	ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	201
TABLE 174	ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	201
TABLE 175	ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	202
TABLE 176	ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	202
TABLE 177	ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	203
TABLE 178	ASIA PACIFIC RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	203
10.4.1	ASIA PACIFIC: RECESSION IMPACT	203
10.4.2	JAPAN	204
10.4.2.1	Availability of universal healthcare reimbursement policy and growth in geriatric population to drive market	204
TABLE 179	JAPAN: KEY MACROINDICATORS	204
TABLE 180	JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)	205
TABLE 181	JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)	205
TABLE 182	JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)	205
TABLE 183	JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)	206
TABLE 184	JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)	206
TABLE 185	JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)	206
TABLE 186	JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)	207
TABLE 187	JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)	207
TABLE 188	JAPAN RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)	207

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

#### 10.4.3 CHINA 208

10.4.3.1 Modern healthcare systems and improved reimbursement policies to drive market 208

TABLE 189 CHINA: KEY MACROINDICATORS 208

TABLE 190 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION) 209

TABLE 191 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) 209

TABLE 192 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION) 209

TABLE 193 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION) 210

TABLE 194 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION) 210

TABLE 195 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION) 210

TABLE 196 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION) 211

TABLE 197 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION) 211

TABLE 198 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) 212

#### 10.4.4 INDIA 212

10.4.4.1 Large patient population and availability of skilled medical professionals to drive market 212

TABLE 199 INDIA: KEY MACROINDICATORS 212

TABLE 200 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION) 213

TABLE 201 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) 213

TABLE 202 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION) 213

TABLE 203 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION) 214

TABLE 204 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION) 214

TABLE 205 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION) 214

TABLE 206 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION) 215

TABLE 207 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION) 215

TABLE 208 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) 216

#### 10.4.5 AUSTRALIA 216

10.4.5.1 Growing prevalence of chronic lung diseases to drive market 216

TABLE 209 AUSTRALIA: KEY MACROINDICATORS 216

TABLE 210 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION) 217

TABLE 211 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) 217

TABLE 212 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION) 217

TABLE 213 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION) 218

TABLE 214 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION) 218

TABLE 215 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION) 218

TABLE 216 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION) 219

TABLE 217 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION) 219

TABLE 218 AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) 220

#### 10.4.6 SOUTH KOREA 220

10.4.6.1 Increasing geriatric population and rising disposable income to drive market 220

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Respiratory Diagnostics Market by Product & Services (Devices, Reagents, Software), Test (PFT, Peak Flow, Spirometry), OSA, Imaging (X-ray, CT, MRI, PET), Molecular (PCR, DNA Sequencing), Indication (Lung Cancer, Asthma, COPD, TB) - Global Forecast to 2029**

Market Report | 2023-11-28 | 338 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

Signature